BNGO · Bionano Genomics, Inc.
$1.18
+0.00 (+0.00%)
At close · Aug 14
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, based on recurring losses from operations incurred since inception, the expectation of continued operating losses, and the need to raise additional capital to finance our future operations, we determined that there is substantial doubt about our ability to continue as a going concern within 12 months after the date that the financial statements included in this Quarterly Report are issued.”View the 10-Q filed Aug 10, 2026
Market Cap
$13.90M
Shares
11.78M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$28.51M
-7.4%
FY2025
Net Income
-$26.4M
+76.4%
FY2025
Gross Margin
46.25%
+45pp
FY2025
Operating Margin
-116.95%
+220.9pp
FY2025
Diluted EPS
-$4.85
+94.5%
FY2025
Operating Cash Flow
-$16.35M
+76.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| $30.18M | $28.51M | $30.78M | $36.12M | $27.8M | $17.98M | $8.5M | $10.13M | $12M | $9.51M | |
| $15.84M | $15.32M | $30.4M | $26.55M | $21.86M | $14.11M | $5.73M | $6.77M | $8.71M | $6.03M | |
| $14.34M | $13.19M | $380K | $9.57M | $5.95M | $3.87M | $2.77M | $3.36M | $3.29M | $3.47M | |
| — | 46.25% | 1.23% | 26.49% | 21.38% | 21.54% | 32.61% | 33.18% | 27.41% | 36.55% | |
| $12.2M | $11.37M | $24.8M | $54.03M | $49.05M | $22.49M | $10.26M | $9.08M | $9.48M | $12.01M | |
| $34.33M | $35.15M | $51.86M | $92.76M | $88.6M | $58.49M | $31.07M | $20.16M | $14.22M | $14.08M | |
| — | $5.4M | $6.6M | $7.2M | $5.8M | $1.4M | $100K | — | — | — | |
| — | $9.53M | $14.02M | $13.71M | $9.62M | $3.35M | $1.48M | $1.13M | $1.32M | $1.5M | |
| — | $0 | — | — | — | — | — | — | — | — | |
| $46.53M | $46.52M | $104.36M | $224.81M | $137.64M | $80.98M | $41.32M | $29.24M | $23.7M | $26.69M | |
| -$32.19M | -$33.34M | -$103.98M | -$215.25M | -$131.7M | -$77.1M | -$38.55M | -$25.87M | -$20.42M | -$23.22M | |
| — | -116.95% | -337.87% | -595.98% | -473.7% | -428.79% | -453.38% | -255.44% | -170.12% | -244.28% | |
| — | -$23.81M | -$89.96M | -$201.54M | -$122.08M | -$73.75M | -$37.07M | -$24.75M | -$19.09M | -$21.71M | |
| $5.17M | — | — | $5.12M | $298K | $927K | $2.52M | $2.29M | $1.38M | $590.93K | |
| — | $1M | $1.5M | $3.3M | $1.5M | $400K | — | — | — | — | |
| $94K | $7.01M | -$8M | -$17.19M | $986K | -$1.05M | -$2.53M | -$3.92M | $1.93M | -$128K | |
| -$32.1M | -$26.33M | -$111.98M | -$232.43M | -$130.71M | -$78.15M | -$41.08M | -$29.79M | -$18.48M | -$23.35M | |
| $67K | $67K | $33K | $62K | $1.88M | -$5.72M | $29K | $21.05K | $15.51K | $18.55K | |
| -$32.16M | -$26.4M | -$112.02M | -$232.49M | -$132.6M | -$72.44M | -$41.11M | -$29.82M | -$18.5M | -$23.37M | |
| — | -92.59% | -363.98% | -643.74% | -476.93% | -402.84% | -483.43% | -294.34% | -154.13% | -245.82% | |
| -$32.14M | -$26.41M | -$112.01M | -$231.35M | -$133.18M | -$72.97M | -$41.11M | — | — | — | |
| USD/shares | — | -$4.85 | -$88.13 | -$408.60 | -$274.80 | -$156.00 | — | — | — | — |
| USD/shares | — | -$4.85 | -$88.13 | -$408.60 | -$274.80 | -$156.00 | — | — | — | — |
| shares | — | 5.45M | 1.27M | 569K | 482.02K | 461.3K | 173.75K | 24.96K | 11.8K | 4501.775 |
| shares | — | 5.45M | 1.27M | 569K | 482.02K | 461.3K | 173.75K | 24.96K | 11.8K | 4501.775 |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 0.62×
EV/EBIT
—
P/E (TTM)
—
Peer medians compare against the 12 similar-size Medical Instruments & Supplies companies (of 48 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | $28,508,000 | $30,776,000 | $36,116,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| EMEA | $14,108,000 | $14,234,000 | $12,963,000 | $8,960,000 | $5,604,000 | $3,163,000 | $3,627,602 |
| Americas | $12,180,000 | $13,649,000 | $18,020,000 | $13,862,000 | $9,329,000 | — | — |
| Asia Pacific | $2,220,000 | $2,893,000 | $5,133,000 | $4,980,000 | $3,048,000 | $851,000 | $1,471,639 |
| North America | — | — | — | — | — | $4,489,000 | $5,030,267 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Consumable Revenue | $13,970,000 | $12,773,000 | $11,157,000 | $6,731,000 | $5,808,000 | $3,145,000 | $2,711,981 |
| Software Revenue | $6,410,000 | $6,192,000 | $5,571,000 | $5,127,000 | $991,000 | — | — |
| Instrument Revenue | $6,363,000 | $8,043,000 | $9,999,000 | $8,567,000 | $5,887,000 | $3,085,000 | $6,762,463 |
| Product And Service Other | $1,765,000 | $3,768,000 | $9,389,000 | $7,377,000 | $5,295,000 | $2,273,000 | $655,064 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | -$33,339,000 | -$103,983,000 | -$215,245,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | -116.9% | -337.9% | -596% |
Key facts
CIK
1411690
CUSIP
09075F404
13F (30d)
36 filings
36 filers
Visit website
Investor relations